Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ALIM

Alimera Sciences (ALIM) Stock Price, News & Analysis

Alimera Sciences logo

About Alimera Sciences Stock (NASDAQ:ALIM)

Key Stats

Today's Range
$5.54
$5.54
50-Day Range
$5.19
$5.60
52-Week Range
$2.61
$5.65
Volume
N/A
Average Volume
376,318 shs
Market Capitalization
$290.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Stock News Headlines

ANI Pharmaceuticals’ Record Growth and Strategic Acquisition
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Alimera Sciences, Inc. (ALIM)
Alimera Sciences Shares Slide on Merger Lawsuit
See More Headlines

ALIM Stock Analysis - Frequently Asked Questions

Alimera Sciences, Inc. (NASDAQ:ALIM) released its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company had revenue of $27 million for the quarter, compared to the consensus estimate of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative trailing twelve-month return on equity of 33.70%.

Shares of Alimera Sciences reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alimera Sciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/06/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALIM
Employees
150
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+44.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-20,130,000.00
Pretax Margin
-14.76%

Debt

Sales & Book Value

Annual Sales
$99.68 million
Book Value
$0.88 per share

Miscellaneous

Free Float
35,939,000
Market Cap
$290.24 million
Optionable
Optionable
Beta
1.25

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:ALIM) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners